Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
Monte Rosa Therapeutics(GLUE) Newsfilter·2024-07-08 12:36BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual UBS Targeted Protein Degradation Day on Monday, July 15, 2024, at 3:30 p.m. ET. Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) ...